| ［1］Vizcaino AP, Moreno V, Lambert R, et al. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995［J］. Int J Cancer, 2002, 99(6):860-868.［2］Prasannan L, Misek DE, Hinderer R, et al. Identification of beta-tubulin isoforms as tumor antigens in neuroblastoma［J］. Clin Cancer Res, 2000, 6(10):3949-3956.［3］高红军，赵晓航. SERPA技术及其在肿瘤相关抗原鉴定中的应用［J］. 医学综述, 2010, 16(18):2853-2855.［4］Fujita Y, Nakanishi T, Hiramatsu M, et al. Proteomics-based approach identifying autoantibody against peroxiredoxin Ⅵ as a novel serum marker in esophageal squamous cell carcinoma［J］. Clin Cancer Res, 2006, 12(21):6415-6420.［5］高红军, 周兰萍, 毛友生, 等. 食管鳞癌肿瘤相关抗原磷酸甘油酸激酶1的鉴定［J］. 世界华人消化杂志, 2008, 16(17):1866-1872.［6］腾梁红, 吕宁, 赵晓航, 等. 组织芯片技术检测食管癌前病变相关预警标志物［J］. 世界华人消化杂志, 2005, 13(1):6-9.［7］Qi Y, Chiu JF, Wang L, et al. Comparative proteomic analysis of esophageal squamous cell carcinoma［J］. Proteomics, 2005, 5(11):2960-2971.［8］Fothergill-Gilmore LA, Watson HC. The phosphoglycerate mutases［J］. Adv Enzymol Relat Areas Mol Biol, 1989, 62:227-313.［9］Scatena R, Bottoni P, Pontoglio A, et al. Glycolytic enzyme inhibitors in cancer treatment［J］. Expert Opin Investig Drugs, 2008, 17(10):1533-1545.［10］Jones RG, Thompson CB. Tumor suppressors and cell metabolism:a recipe for cancer growth［J］. Genes Dev, 2009, 23(5):537-548.［11］Cheung EC, Vousden KH. The role of p53 in glucose metabolism［J］. Curr Opin Cell Biol, 2010, 22(2):186-191.［12］Kondoh H, Lleonart ME, Gil J, et al. Glycolytic enzymes can modulate cellular life span［J］. Cancer Res, 2005, 65(1):177-185.［13］Li Y, Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function［J］. Oncogene, 2007, 26(15):2220-2225.［14］Ren F, Wu H, Lei Y, et al. Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma［J］. Mol Cancer, 2010, 9:81.［15］Pelicano H, Martin DS, Xu RH, et al. Glycolysis inhibition for anticancer treatment［J］. Oncogene, 2006, 25(34):4633-4646.［16］Li C, Xiao Z, Chen Z, et al. Proteome analysis of human lung squamous carcinoma［J］. Proteomics, 2006, 6(2):547-558.［17］Scatena R, Bottoni P, Giardina B. Modulation of cancer cell line differentiation:a neglected proteomic analysis with potential implications in pathophysiology, diagnosis, prognosis, and therapy of cancer［J］. Proteomics Clin Appl, 2008, 2(2):229-237.［18］Saeki H, Kitao H, Yoshinaga K, et al. Copy-neutral loss of heterozygosity at the p53 locus in carcinogenesis of esophageal squamous cell carcinomas associated with p53 mutations［J］. Clin Cancer Res, 2011, 17(7):1731-1740. |
Acta Academiae Medicinae Sinica
